Document is current
Any future updates will be listed below
-
Authors
Schreiber, Stefan
Dignass, Axel
Peyrin-Biroulet, Laurent
Hather, Greg
Demuth, Dirk
Mosli, Mahmoud
Curtis, Rebecca
Khalid, Javaria Mona
Loftus, Edward Vincent Jr.
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
- License Information
-
More Information
Article History
Received: 23 May 2018
Accepted: 24 May 2018
First Online: 4 June 2018
Compliance with ethical standards
:
: Stefan Schreiber has received honoraria from AbbVie, Celltrion, MSD, Pfizer, and Takeda. Axel Dignass has no conflict of interest. Laurent Peyrin-Biroulet has received lecture fees from MSD, Abbvie, Janssen, Takeda, Celltrion, Pfizer, BMS, Pharmacosmos, Shire, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, UCB Pharma, Hospira, Boehringer-Ingelheim, and Lilly. Greg Hather owns stock in Takeda Pharmaceuticals and is an employee of Takeda Global Research and Development. Dirk Demuth is an employee of Takeda International, UK Branch. Mahmoud Mosli has no conflict of interest. Rebecca Curtis is a former employee of Takeda International, UK Branch. Javaria Mona Khalid owns stock in Takeda Pharmaceuticals International and is an employee of Takeda International, UK Branch. Edward V. Loftus, Jr, has received research support from and has served as a consultant for Takeda.
